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A B S T R A C T
Purpose
The anesthetic ketamine is widely used for pain related to cancer, but the evidence to support its
use in this setting is weak. This study aimed to determine whether ketamine is more effective
than placebo when used in conjunction with opioids and standard adjuvant therapy in the
management of chronic uncontrolled cancer pain. Ketamine would be considered of net benefit if
it provided clinically relevant improvement in pain with limited breakthrough analgesia and
acceptable toxicity.
Patients and Methods
In this multisite, dose-escalation, double-blind, randomized, placebo-controlled phase III trial,
ketamine or placebo was delivered subcutaneously over 3 to 5 days.
Results
In all, 185 participants were included in the primary analysis. There was no significant difference between
the proportion of positive outcomes (0.04; 95% CI,0.10 to 0.18; P .55) in the placebo and intervention
arms (response rates, 27% [25 of 92] and 31% [29 of 93]). Pain type (nociceptive v neuropathic) was not
a predictor of response. There was almost twice the incidence of adverse events worse than baseline in the
ketamine group after day 1 (incidence rate ratio, 1.95; 95% CI, 1.46 to 2.61; P .001) and throughout the
study. Those receiving ketamine were more likely to experience a more severe grade of adverse event per
day (odds ratio, 1.09; 95% CI, 1.00 to 1.18; P  .039). The number of patients needed to treat for one
additional patient to have a positive outcome from ketamine was 25 (95% CI, six to). The number needed
to harm, because of toxicity-related withdrawal, was six (95% CI, four to 13).
Conclusion
Ketamine does not have net clinical benefit when used as an adjunct to opioids and standard
coanalgesics in cancer pain.
J Clin Oncol 30:3611-3617. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Pain management is a major problem in cancer
care,1 even in developed countries with access to a
range of opioids and adjuvant therapies. Analgesic
agentsmust providenet clinical benefit—goodpain
relief with acceptable levels of toxicity in a defined
target population.
The dissociative anesthetic agent ketamine is
widely used off label at subanesthetic doses for can-
cer pain, usually in conjunction with opioids. As a
noncompetitive antagonist, ketamine interacts with
N-methyl-D-aspartate receptor complexes, inter-
rupts cholinergic transmission, and inhibits the re-
uptake of noradrenaline and 5-hydroxytryptamine.
Evidence to support the use of ketamine in chronic
cancer pain has been extrapolated from other set-
tings and has been justified primarily from case se-
ries and uncontrolled studies.2-4
Cardiac and neurologic toxicities, including
emergent phenomena (eg, hallucinations, a sense of
disconnection, vivid dreams), have been reported.5
There is also emerging evidence on the deleterious
effect of ketamine on bladder function.6 In light of
these toxicities, definite evidence of clinically signif-
icant pain improvement is necessary for ketamine to
have sufficient net health and economic benefits.7
Theaimof this studywas todeterminewhether
ketamine, delivered subcutaneously with dose titra-
tion over 5 days has greater clinical benefit than
placebo,whenused in conjunctionwithopioids and
standard adjuvant therapy, in the management of
chronic uncontrolled pain related to cancer or
its treatment.
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PATIENTS AND METHODS
Eligibility and Enrollment
Participants were recruited from 10 palliative care services in a range of
metropolitan settings across Australia.8 Eligible patients were in-patients age
18 years orolder.Allmet thedefinitionof refractory chronicpain secondary to
cancer or its treatment9 with a Brief Pain Inventory (BPI)10 average pain score
of 3 despite ongoing treatment with opioids and coanalgesics at predefined
dose levels (Appendix Table A1, online only). Patients were excluded if they
had receivedketamine for chronicpainwithin6months, radiotherapy to a site
of pain within 2 weeks, any other procedure or therapy likely to affect pain
during the trial period, or comorbidities contraindicating the use of ket-
amine.11 All participants were formally assessed for cognitive ability to under-
take trial requirements (Fig 1).
Interventions
Nochangeinbaselineopioiddoseorcoanalgesiawasallowedinthe48hours
before study commencement. No increase in baseline opioid dose was allowed
during the study, but participants had access to breakthrough analgesia. Opioid
dose reductionwasallowed forpainresponseoropioid toxicity.Totaldailyopioid
dose andnumber of breakthrough analgesic doseswere recorded.
Subcutaneous infusions of placebo (normal saline) or ketamine at three
dose levels (100, 300, or 500 mg) were prepared by diluting ketamine hydro-
chloride 200 mg/2 mL in normal saline to a set volume. Participants received
either ketamine or placebo in a 5-day schedule, starting at the first dose level
(100mg/24hours; Fig 2). Pain and toxicity assessmentswereundertakenevery
24 hours by trained research staff. Least, average, and worst pain over the
preceding 24 hours were assessed by using the BPI. If 80% of study drug had
beendelivered, andaveragepain improvedby2BPIunitswithnomore than
four breakthrough doses, the dose remained the same. If not, the dose was
increased to the next level. Any psychomimetic toxicity was treated promptly
with haloperidol or midazolam at specified doses. Dose reduction to the
previous level was allowed in the case of unacceptable toxicity. Study drugwas
discontinued before 5 days if toxicity was intolerable or if there was no re-
sponse after 24 hours at 500mg.
Randomization and Masking
Each site pharmacy used randomization tables from an independent
central registry. Stratification was by pain type (neuropathic or nociceptive),
according to the Leeds Assessment of Neuropathic Symptoms and Signs
(LANSS) scale.12 Randomization was double blinded, allocated by blocks of
four in a 1:1 ratio for each strata by site. All nonpharmacy study staff, treating
clinicians, investigators, andparticipantswereunawareof treatmentallocation
until completion of all data collection and analysis.
Definition of a Clinically Relevant Improvement in Pain
A clinically relevant improvement in pain was defined as a reduction in
BPIaveragepain scoreby2points frombaseline in theabsenceofmore than
four breakthrough doses of analgesia over the previous 24 hours.13
Completion
Participants were defined as having completed the study if they had
received studydrug for 5days, or received24hours of studydrug atmaximum
Assessed as eligible
(N = 194)
Randomly assigned
(n = 187)
Not randomly assigned (n = 7)
  Did not consent (n = 2)
  Changed mind (n = 2)
  Clinical request (n = 1)
  Hospital transfer (n = 1)
  Study medication not available (n = 1)
Deleted from analysis
(n = 2)
Allocated to ketamine
(n = 93)
Allocated to placebo
(n = 92)
Did not receive ketamine (n = 2)
  Withdrew consent (n = 1)
  Changed therapy (n = 1)
Received ketamine 
(n = 91)
Received placebo
(n = 90)
Completed ketamine
(n = 75)
Completed placebo
(n = 74)
Received 5 days of 
treatment with ketamine
(n = 39)
Received 5 days of 
treatment with placebo
(n = 35)
Discontinued ketamine (n = 16)
  Clinical deterioration (n = 7)
  Patient/clinical request (n = 5)
  Change in therapy (n = 4)
Treatment failure (n = 19)
  (24 hours at maximal dose)
Treatment failure (n = 17)
  (discontinued because
   of toxicity)
Did not receive placebo (n = 2)
  Clinical request (n = 1)
  Patient request (n = 1)
Discontinued placebo (n = 16)
  Clinical deterioration (n = 5)
  Patient/clinical request (n = 6)
  Change in therapy (n = 5)
Treatment failure (n = 37)
  (24 hours at maximal dose)
Treatment failure (n = 2)
  (discontinued because
   of toxicity)
Fig 1. CONSORT diagram.
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dose (500mg)withnoclinically relevant improvement inpain,or if studydrug
was withdrawn because of unacceptable toxicity at any dose level.
Outcomes
The primary outcome measure was a positive response, defined as a
clinically relevant improvement in pain at the end of the 5-day study period.
Other outcomes were considered to be a negative response.
Secondary outcome measures included pain assessments at days 2 to
5 and adverse events graded according to the National Institutes of Health
Common Terminology Criteria for Adverse Events, version 3.0.14
Psychomimetic-specific events were assessed daily using the Clinician-
Administered Dissociative States Scale (CADSS).15
Sample Size
A total of 150 participants who met the definition of completion were
required toprovide85%power todetect a25%absolutedifference in response
ratewith a two-tailed type I errorof 0.05.This assumedapositive response rate
of 30%in theplaceboarm.Aresponse rateof at least 55%in the active armwas
required to show net clinical benefit, given the expected ketamine toxicity.
Statistical Methods
Theprimary analysiswas an intention-to-treat analysis. The response for
participants stopping study drug before day 5 for reasons unrelated to the
intervention was imputed from the last recorded assessment of pain. For the
primary analysis, the proportions of patients having a positive response in
the ketamine and placebo groups were compared by using a 2 test. Possible
differential response rates in neuropathic and non-neuropathic pain and pre-
dictors of toxicitywere examinedbyusingmixed effects logistic regression.All
longitudinal outcomes, pain (least, average, andworst), severity and incidence
of adverse events, and psychotoxicity were analyzed as three-level random
effects models (readings nested within participants nested within sites) by
using generalized linear latent and mixed models with robust SEs and the
appropriate distribution and link. Log time or time squared was added as
appropriate (by minimizing Akaike information criterion and/or Bayesian
information criterion) to improve model fit. All models were fitted with
adaptive quadrature and eight numerical integration points and then refitted
with 16 numerical integration points with almost identical estimates in all
No
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Clinically significant
improvement in pain?
Acceptable toxicity
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Fig 2. Study diagram.
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cases. A Cox proportional hazards frailty model was used to assess the associ-
ation between survival and treatment. The covariates, link, and distribution
that comprise the model type are summarized in Appendix Table A2 (online
only). Regression results are reported as odds ratios (ORs), incidence rate
ratios, or  coefficients as appropriate with 95%CIs.
The number needed to treat for clinically relevant pain response and
number needed to harm for toxicity resulting from the use of ketamine are
reported with 95%CIs, truncated atwhen the result is not significant.
Ethical and Safety Oversight
The study was approved by ethics committees at all sites andmonitored
by a safetymonitoring committee. All participants providedwritten informed
consent. A blinded interim analysis was undertaken for safety only. The study
was publically registered (ANZCTR [Australian New Zealand Clinical Trials
Registry]12607000501448).TheAustralianGovernment funded the studybut
had no role in trial design, data analysis, or writing of the report, apart from
delegated oversight of the Palliative Care Clinical Studies Collaborative
(PaCCSC)Management Advisory Board.
RESULTS
Baseline Data
There was no significant association between intervention and
control arms and any observed covariate in baseline demographic or
clinical characteristics (Table 1).
Table 1. Baseline Demographics
Characteristic
Ketamine (n  93) Placebo (n  92)
No. % Mean SD No. % Mean SD
Age, years 63.0 13.7 64.3 9.9
Male sex 50 55.0 53 58.2
Site of cancer diagnosis
Lung 22 24.2 18 19.8
Prostate 13 14.3 11 12.1
Colorectal 8 8.8 14 15.6
Gynecologic 8 8.8 3 3.3
Breast 6 6.6 11 12.1
Bone/soft tissue 5 5.6 2 2.2
Pancreas 5 5.5 5 5.5
Other 26 28.6 26 28.9
Performance status (AKPS)
Median 60 60
Interquartile range 50-60 50-60
Background opioid dose OME, mg
Median 300 410
Interquartile range 160-480 258-700
BPI pain score
Average 5.43 1.3 5.21 1.4
Worst 8.08 1.5 7.64 1.6
Least 2.47 1.7 2.37 1.9
LANSS score  12 28 30.1 28 30.4
CADSS score
0 55 59.8 54 60.4
1-2 19 20.7 14 15.4
3-8 12 13.0 14 15.4
9 6 6.5 8 8.8
Concomitant medications
Antipsychotics 1 1.1 3 3.3
Benzodiazepines 9 9.7 15 16.3
Adverse events†
Somnolence 39 45.4 32 35.2
Constipation 37 44.1 42 46.7
Nausea/vomiting 26 28.3 21 22.6
Dizziness 14 16.3 21 23.1
Cognitive disturbance/confusion 9 9.7 9 9.8
Hypertension 7 8.1 4 4.4
Cardiac arrhythmia 6 6.9 4 4.6
Hypoxia 6 7.1 11 12.4
Site irritation 5 5.9 5 5.49
Other 2 2.2 6 6.5
Abbreviations: AKPS, Australian-modified Karnofsky performance status scale; BPI, Brief Pain Inventory; CADSS, Clinician-Administered Dissociative States Scale;
LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; OME, oral morphine equivalents; SD, standard deviation.
All P values  .05; no allowance was made for missing data.
†Any grade.
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CONSORT Recruitment and Participant Flow
There were 187 participants randomly assigned over 3 years
(March 2008 to February 2011). One participant was recruited
twice, and the second set of observations was deleted from the data
set. The other was randomly assigned but did not meet eligibility
criteria. The intention-to-treat sample therefore comprised 185
patients (ketamine, 93; placebo, 92). Of these, 149 met the defini-
tion of completion. Seventy-four participants received study drug
on all 5 days.
Primary Analysis
Four of the 185 randomly assigned participants who withdrew
before the commencement of study drug were deemed to have a
negative response.The responsewas27%(25of92) in theplaceboand
31% (29 of 93) in the intervention arm with no difference (P .55)
between the proportion of positive outcomes in each group (0.04;
95%CI,0.10 to 0.18).
There was no difference in outcome in participants whomet the
definition of completion (n  149; 33% v 26%; P  .231), in the
subgroup that received 5 days of study drug (n  74; 64% v 54%;
P  .39), or when all participants with baseline pain scores were
included (n  181; 32% v 28%; P  .55). When the primary
analysis was completed by using worst pain but not average pain,
the placebo response was 23% (21 of 92) and the intervention
response was 27% (25 of 93; P .52). The corresponding sensitiv-
ity analysis also remained nonsignificant. When the definition of
positive response was varied by requiring average pain to improve
by 3 BPI units, no significant difference was found between arms
for any level of pain improvement.
The number needed to treat for one additional patient to get a
positive outcome from ketamine was 25 (95% CI, six to ). The
number needed to harm measured by actual withdrawal because of
unacceptable toxicity was six (95%CI, 4 to 13).
Secondary Analyses
Baseline data were provided by 181 participants. The number of
participants and responders by group and baseline average pain score
is shown in Figure 3. There was no difference in response between
arms and baseline pain (P  .15). Pain type (nociceptive v neuro-
pathic) was not a statistically significant predictor of response.
Multivariable analyses of pain scores were conducted, with pain
as a continuous outcome. Themean difference in pain between arms/
day was greatest for worst pain. By study end, mean worst pain score
was 6.01 (95%CI, 5.44 to 6.59) for placebo and 5.30 (95%CI, 4.74 to
5.86) forketamine(P .034).Thedifference inabsolute terms is small
(0.71) and was not clinically significant because the difference was
not 2 BPI units. For average pain, there was no difference in mean
pain levels between arms by study end (placebo, 3.49 [95%CI, 3.02 to
3.95] vketamine, 3.11 [95%CI, 2.65 to3.57)];P .15).Therewereno
differences between groups at any time for least pain. The trajectory of
pain scores over time is modeled in Figure 4 for each pain category.
Corresponding sensitivity analyses were conducted for the 74 partici-
pants who received study drug over 5 days and the 149 who met the
definition of completion. In the former, there was no difference in
pain between arms at study end, and in the latter, the results were
almost identical to theanalysis for181patients.Whenpainwas treated
as an ordinal outcome, compared with baseline, both arms were less
likely to report a higher pain score by day 3 until the end of study
period, with no significant differences between groups on any day
(P  .08). The maximum dose received by participants (Table 2)
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Fig 4. Mean pain scores over time (adjusted for arm, time, arm time, In[time],
background opioid dose, age, sex, and pain type [n  181]). P values are
differences between arms at study end. Error bars represent 95% CIs. BPI, Brief
Pain Inventory.
Table 2. Maximum Dose Received by Participants in Each Arm
Ketamine/Placebo
Dose (mg)
No. of Patients Who
Received Ketamine
No. of Patients Who
Received Placebo
 100 6† 7‡
100 16 12
300 35 19
500 36 54
Participants were required to have received at least 80% of planned dose to
complete that dose level.
†Two patients withdrew before start of treatment, and four withdrew during
day 1 before 80% of dose step 1.
‡Two patients withdrew before start of treatment, and five withdrew during
day 1 before 80% of dose step 1.
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differed between arms (P .03). Proportionally more participants in
the ketamine arm comparedwith the placebo armwithdrew from the
study at 300mg (P .005).
The median number of breakthrough analgesic doses given on
day 1 to the placebo arm was three (interquartile range, one to four)
and to the intervention armwas two (interquartile range, one to four;
range, zero to 10 in both groups). This remained similar throughout,
with no difference between arms on any day (P .18). For each pain
category, participants weremore likely to receive breakthrough doses
with each BPI unit increase in pain: OR for least pain, 1.22 (95% CI,
1.11 to1.33),OR for averagepain, 1.59 (95%CI, 1.45 to1.74), andOR
for worst pain, 1.61 (95%CI, 1.46 to 1.78).
Adverse event scores recorded asworse than those at baseline are
shown in Table 3. There was almost twice the incidence of adverse
events gradedworse thanbaseline in theketaminearmcomparedwith
the placebo armat the endof day 1 (incidence rate ratio, 1.95; 95%CI,
1.46 to 2.61; P .001) and throughout the study. Participants receiv-
ing ketamine were more likely to experience a more severe grade of
adverse event per day (OR, 1.09; 95% CI, 1.00 to 1.18; P  .039).
Injection site reactionswere nearly three timesmore likely each day in
the ketamine group (OR, 2.85; 95%CI, 1.77 to 4.73; P .001). There
were relatively few adverse events higher than grade 3 in severity and
worse than baseline (14 for ketamine; 16 for placebo). The most
commonwere light-headedness (five cases), hypoxia (five cases), and
somnolence (nine cases). Seven serious adverse events were reported,
two of which (bradyarrhythmia and cardiac arrest, both in patients
receiving ketamine)were thought to be possibly related to study drug.
There was no difference in psychotoxicity at baseline, with ap-
proximately 40% of all participants having a positive CADSS score.
Because the distribution of CADSS scores was exponential (skewed
toward zero), a two-stage analysiswas conducted. Comparedwith the
odds of the placebo group, the odds of the ketamine group experienc-
ingpsychotoxicity increasedeachday,becomingsignificantafterday3
(OR, 2.53; 95% CI, 1.11 to 5.78; P  .027). For those with toxicity,
when the level of toxicity between arms was compared, the ketamine
groupwasmore likely to report higher scores each day (P .093). By
study end, the difference between groups was significant (  0.46;
95%CI, 0.4 to 0.88; P .034).
DISCUSSION
This large randomized controlled trial (RCT) demonstrated a strong
placebo effect and failed to show any additional clinical benefit for
ketaminewhendelivered subcutaneously inadose-escalating regimen
over 5days,while significantly increasing toxicity.Meanpain scores in
this study improved over time for all participants irrespective of allo-
cation, with no difference between arms. Although therewas a greater
improvementperday in theketaminegroup inworst andaveragepain
scores, this never reached a level that would be considered clinically
relevant. The consistency of the results across secondary outcomes
and the fact that the study was adequately powered to detect our
prespecified differences in response, suggests that type II error is not
a factor.
Ketamine is commonly used for themanagement of pain related
to cancer.Although there aremany anecdotal reports of efficacy in the
literature, the RCT evidence to support the use of ketamine in this
patient group to date has been limited to two underpowered trials.16
There is considerable variation in dose, route of delivery, and fre-
quency of use of ketamine with no standard regimen to guide clinical
practice or research. The method of delivery—subcutaneously in a
dose-escalating regimen over 5 days—chosen for this trial came from
the largest case series in the literature.3
The high placebo response rate (27%) has been demonstrated
before, especially in neuropathic pain trials.17-19 Possible explanations
for placebo responses of this order ofmagnitude include regression to
themean(ie, patients aregenerally enrolledonto trialswhen theirpain
isworst, and somewill improve over timewithout treatment), patient
expectation of benefit, and the extra care and attention given to pa-
tients participating in trials.20 Of note, there was no difference in the
number of participants in each arm who had marked improvements
in pain.
The frequency of adverse events at baseline, before the initiation
of any study drug, reflects the toxicity of other medications or the
disease process itself. The adverse events seen in the placebo arm
reflect either a nocebo effect21 or the cumulative toxicity of concomi-
tant medications. Previous studies in this population group have
pointed to the large number of medications per patient and the fre-
quency of drug-related adverse events.22 The greater incidence of
adverse events in the ketamine arm comparedwith the placebo arm is
consistentwith the finding that significantlymore participants receiv-
ing ketamine withdrew because of toxicity. This difference persisted
for 5 days, despite the fact that many participants had withdrawn
because of toxicity. Despite no difference between arms at baseline in
the use of drugs commonly used to treat ketamine toxicity (benzodi-
azepines and antipsychotics), there was more psychotoxicity in the
ketamine arm. The CADSS was developed to measure present-state
dissociative symptoms and has been used as a measure of perceptual,
behavioral, and attention alterations occurring during dissociative
experiences in normal volunteers given ketamine.15,23 Both the pres-
ence and level of psychotoxicity was significantly greater in the ket-
amine arm compared with the placebo arm by study end. Although
CADSS scores were relatively low in the majority of participants, the
results were driven by a subgroup in the ketamine arm with high
scores. Irritation at subcutaneous infusion sites was also significantly
more frequent in those receiving ketamine but was not sufficient to
unblind the study. Importantly, for each person observed to achieve a
Table 3. Number of Adverse Events That Occurred During the Trial for
Which the Grade Was Worse Than at Baseline
Adverse Event Ketamine Placebo
Cardiac arrhythmia 2 3
Cognitive disturbance 17 8
Confusion 13 9
Constipation 13 7
Dizziness 17 10
Hypertension 3 8
Hypoxia 7 8
Site irritation 31 4
Somnolence 24 17
Nausea 15 8
Vomiting 10 9
Other 20 12
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benefit in pain control from ketamine, four people suffered enough
from toxicity to cause them to withdraw.
This studymay be criticized in that the populationwas heteroge-
neous. The study group is typical, however, of those patients com-
monly referred to a palliative care service and who receive ketamine
for pain. The participants were unwell, with multiple comorbidities
andcomedications.Themedian survivalwas 2months inbothgroups
(data not shown). A median performance status of 60 at baseline
indicates the need for some assistancewith activities of daily living. All
had chronic refractory pain with defined prior treatment to which
there had been an incomplete response. A baseline median oral mor-
phine dose of more than 300 mg/d suggests that most patients had
been taking opioids for some time. In addition, we imputed pain
scores at study end for missing data by using the last available score.
Although multiple imputation could alternatively be applied,24 this
study would have required, at a minimum, imputation of pain scores
and the number of breakthrough analgesic doses for each day of
absent data, resulting in considerable random variation by study end.
RCTs inpatientswith life-limitingdisease are challengingandare
considered by some to be inappropriate and/or unfeasible.25 This
studydemonstrates that it ispossible toundertakehigh-quality studies
inpatientswith life-limitingdiseaseandthatplaceboarmsareessential
in the absence of a comparator of proven benefit. In many uncon-
trolled studies, impressive response rates are little different from the
placebo response demonstrated in this trial.26
In conclusion, this adequately powered RCT fails to support the
current widespread practice of using subcutaneous ketamine as an
adjuvant to opioids in the management of refractory pain in patients
with advanced cancer.
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